title: [Site-directed mutagenesis of human IL-29 and antineoplastic activity of the recombinant human IL-29 variant].
abstract: To explore the anti-tumor proliferation activity of human interleukin-29 (hIL-29) variant and based on bioinformatics analyzed data of hIL-29, a mutant gene hIL-29(mut33,35) was amplified by site-directed mutagenesis and megaprimer PCR. The hIL-29(mut33,35) was inserted into an eukaryotic expression plasmid pPIC9K and successfully expressed in Pichia pastoris GS115. A recombinant variant protein (rhIL-29(mut33,35)) was purified from the ferment supernatant of the engineering GS115. To observe the antineoplastic activity of the variant rhIL-29(mut33,35), a CCK-8 reagent was used to detect the anti-proliferation effect. Results show that it has strong anti-proliferation effect when acted on liver cancer cell BEL7402, colon cancer cell HCT8 and gastric cancer cell SGC7901. The inhibition ratios of the three tumor cells were (30.99 ± 1.58)%, (22.47 ± 1.37)% and (32.05 ± 2.02)%, respectively. In high dose group, the anti-proliferation effect of the rhIL-29(mut33,35) was stronger than that of wild type rhIL-29 (P < 0.01). This indicates the variant rhIL-29(mut33,35) has potential development value for medicine.
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Rong
authors.initials: R
authors.lastname: Zhu
authors.forename: Chunlei
authors.initials: C
authors.lastname: Ge
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lu
authors.forename: Liyun
authors.initials: L
authors.lastname: Li
authors.forename: Fei
authors.initials: F
authors.lastname: Li
authors.forename: Minchen
authors.initials: M
authors.lastname: Wu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000096:biosynthesis / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000473:pathology; D016297:Mutagenesis, Site-Directed; D010843:Pichia; D010957:Plasmids; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000494:pharmacology; D000095022:Interferon Lambda
chemical_list: D000970:Antineoplastic Agents; D007372:Interferons; D007378:Interleukins; D011994:Recombinant Proteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda